Verseon International Corporation has announced that its noval AI technology, VersAI™, demonstrates superior prediction accuracy compared to current state-of-the ...
Presented at ESMO 2024, the Phase 2 PHAROS trial revealed that BRAFTOVI® and MEKTOVI® combination therapy has significant long-term benefits for patients with BRAF V600E-mutant metastatic non-small ...